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The aim of the present study was to assess whether flushing the donor liver with urokinase immediately before implanta-
tion reduces the incidence of nonanastomotic biliary strictures (NASs) after liver transplantation, without causing increased
blood loss, analyzed as a historical cohort study. Between January 2005 and October 2012, all liver (re-)transplantations
were included. Of the 185 liver transplant recipients included, 63 donor livers between January 2010 and October 2012
received urokinase (study group), whereas the donor liver of 122 consecutive recipients, who served as a historical control
group, between January 2005 and January 2010 did not receive urokinase. Basic donor (Eurotransplant donor risk index)
and recipient (age, body mass index, laboratory Model for End-Stage Liver Disease score) characteristics did not signifi-
cantly differ in both groups. Thirty-three recipients developed NASs: 22 in the control group (18%) and 11 (17.5%) in the
study group (P5 0.68). Analyzed separately for donation after circulatory death (P5 0.42) or donation after brain death
(P5 0.89), there was no difference between the groups in incidence of NAS. Of all the recipients developing NAS, 7
(21%) needed retransplantation and all others were treated conservatively. Autologous blood transfusion requirements did
not differ significantly between both groups (P5 0.91), whereas interestingly, more heterologous blood transfusions were
needed in the control group (P< 0.001). This study has its limitations by its retrospective character. A multi-institutional
prospective study could clarify this issue. In conclusion, arterial flushing of the liver with urokinase immediately before
implantation did not lead to a lower incidence of NAS in this study, nor did it lead to increased blood loss.
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Biliary complications are a well-known, major cause of
morbidity and graft failure in recipients after liver
transplantation.(1,2) The most troublesome are the
so-called nonanastomotic biliary strictures (NASs),
with an incidence of 5%-15% reported in most current
studies,(3,4) and in up to 30% of patients receiving a
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liver from donation after circulatory death (DCD).(5)
With direct treatment of strictures, by using endo-
scopic or percutaneous cholangiographic dilatations
and stenting, more than 50% of patients with NASs
can be treated successfully.(6-11)
The pathophysiology of NAS development still
remains unknown. Over the years, several risk factors
have been indicated, suggesting that its origin may be
multifactorial. In addition to immunological injury and
bile salt–induced injury, it is suggested that ischemia
injury to the peribiliary vascular plexus plays a critical
role.(12) During the donor procedure, the peribiliary
arterial plexus may not be completely flushed out.
Because the blood supply to the biliary tract is solely
dependent on arterial inflow, these microcirculatory
disturbances in the peribiliary plexus may lead to
obstruction and may subsequently result in insufficient
bile duct preservation.(13,14)
Three previous studies with historical controls sug-
gest that adding a thrombolytic agent, such as uroki-
nase or tissue plasminogen activator (tPA) to the
preservation fluid (after trimming of the donor liver,
on the back table, or before completion of the portal
vein anastomosis), seems to reduce the incidence of
NAS. The hypothesis was that this might be the result
from dissolving microthrombi in the microvascular sys-
tem of the biliary tree.(15-17)
The aim of the present study was to assess whether
flushing the donor liver with urokinase directly before
transplantation reduces the incidence of NAS without
causing increased blood loss.
Patients and Methods
Between January 2005 and October 2012, all ortho-
topic liver transplantations at the Leiden University
Medical Center (Leiden, the Netherlands) were
included in this study.
Exclusion criteria were domino, split, or auxiliary liver
transplantations. Clinical information was obtained
from a prospectively collected database. Covariates
included donor demographics, recipient demographics,
pretransplant information, intraoperative data, and post-
operative outcomes. Calculated laboratory Model for
End-Stage Liver Disease (labMELD) scores were
included in the recipient analysis.
The labMELD score was calculated using laboratory
data (creatinine, bilirubin, international normalized
ratio) and did not include exception points that were
given for liver malignancies or other medical conditions.
On the basis of existing literature, a protocol change
was made as of January 2010 to flush the donor liver
with urokinase, directly before transplantation. This
protocol change was approved by the institutional
ethics committee.
DEFINITION OF NAS
NAS was defined as described by Ten Hove et al.(18)
NAS was any stricture or irregularity of the intrahepatic or
extrahepatic bile ducts of the liver graft that was at least
1 cm above the anastomosis, with or without dilation and
with or without biliary sludge formation, and treated
endoscopically with endoscopic retrograde cholangiopan-
creatography and dilation and/or stenting, percutaneously
with percutaneous transhepatic cholangiography and bili-
ary drainage or by surgical intervention. Therefore, all
these NASs were clinically significant. Hepatic artery
thrombosis (HAT) by either Doppler ultrasound, or con-
ventional angiography, as well as isolated strictures/steno-
sis at the bile duct anastomosis and related dilations were,
by definition, excluded from analysis.
OPERATIVE TECHNIQUES
The procurement of organs was performed as
described by the Eurotransplant protocol. During pro-
curement, the donor liver was flushed with preserva-
tion fluid under a pressure of 300mm Hg (the type of
perfusion fluid used depended on the country where
the procurement took place within the Eurotransplant
region). During procurement in DCD liver allografts,
5000 IU of heparin was administered during initial
organ perfusion. In donation after brain death (DBD)
liver allografts, 300 IU/kg of heparin was administered
5 minutes before cross-clamping. After procurement,
the liver was sent to our hospital. Since January 1,
2010, as a change in center protocol, after inspection
of the donor liver and immediately before implanta-
tion, the hepatic artery was flushed with 250,000 IU of
manually pressurized urokinase on the back table.
Hereafter, the hepatic artery was clamped to prevent
backflow. After a minimum period of 10 minutes after
flushing with urokinase, the hepatic artery was flushed
with 500mL of preservation fluid (histidine trypto-
phan ketoglutarate [HTK] or University of Wisconsin)
in order to prevent systemic introduction of urokinase.
Also, according to standardized protocol, the portal
vein was flushed with 150mL of albumin during caval
anastomosis in order to prevent systemic introduction
of urokinase. Further implantation of the liver allograft
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was done according to protocol. Before January 1,
2010, the same protocol was carried out, only without
administration of urokinase. After consultation of the
medical ethics committee, recipients did not have to
give informed consent because the administration of
urokinase was implemented as a new center protocol.
STATISTICAL ANALYSIS
Continuous variables were presented as median (range)
and standard deviation, whereas categorical variables were
presented as number and percentage. Patient and graft sur-
vival curves and the cumulative incidence of NAS were cal-
culated using the Kaplan-Meier method and compared
using the log-rank test. Categorical variables were com-
pared with the Pearson’s chi-square test or Fisher’s exact
test, where appropriate. Characteristics of the donor, trans-
plantation, and recipient were analyzed using the 2-tailed
Student t test. Blood loss was analyzed using the Mann-
Whitney U test. The level of significance was set at 0.05.
Statistical analyses were performed using SPSS software
version 22.0 forWindows (SPSS Inc., Chicago, IL).
POWER ANALYSIS
With an anticipated reduction of NAS from 45% to
10% on the basis of previous studies on DCD liver
transplantation,(15-17) the power of this study would be
83.2% when comparing 28 DCD livers in the study
group to 17 DCD livers in the control group.
With an anticipated reduction of NAS from 20% to
5% on the basis of previous studies concerning DBD
liver transplantation, the power of this study would be
80.1% when comparing 94 DBD livers in the study
group to 46 DBD livers in the control group.
Results
Of the 205 patients who received a liver transplanta-
tion between January 2005 and October 2012, 5
recipients were excluded based on missing informa-
tion on receiving urokinase, 3 recipients were
excluded based on protocol deviation (Fig. 1). Of the
197 liver recipients remaining for the study, 127
donor livers did not receive urokinase (historic control
group), and 70 donor livers received urokinase (study
group).
In the historic control group, 5 recipients were
excluded (4 split-liver transplantations, 1 domino
donor), leaving 122 recipients in this group. In the
study group, 7 recipients were excluded (6 split-liver
transplantations, 1 domino donor), leaving 63
recipients.
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FIG. 1. Study design.
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Table 1 shows the basic donor and recipient character-
istics of both groups. The mean Eurotransplant donor
risk index (ET-DRI)(19) in the control group was
1.86 0.3 (range, 1-3.1), in the study group 1.86 0.4
(range, 1-2.6; P5 0.56). Of 3 donors, the ET-DRI
could not be calculated. Of the donors in the control
group, 51% were female versus 48% in the study group
(P5 0.76). Donor body mass index was lower in the
control group than in the study group. The mean cold
ischemia time (CIT) of the transplanted livers in the
control group was 5726 142 minutes (224-1090
minutes), in the study group 5356 129 minutes
(range, 230-850 minutes; P5 0.09). The mean first
warm ischemia time in the control group was 16.76 5
minutes (range, 11-31 minutes), in the study group
17.66 6 minutes (range, 9-31 minutes; P5 0.60).
The mean labMELD score in the control group was
16.66 8.7 (range, 6-40), in the study group 16.66 8.9
(range, 6-40; P5 0.99).
BILIARY COMPLICATIONS
In total, 33 (17.8%) recipients developed NASs, of
which 22 (18%) recipients were in the control group,
and 11 (17.5%) recipients were in the study group.
None of the recipients had evidence of HAT or stenosis.
The mean follow-up in the control group was
15436 1049 days (range, 1-3278 days) versus
6756 495 days (range, 1-1434 days) in the study group.
The median number of days of follow-up was
17316 1049 days (range, 312-2356 days) in the study
group versus 7316 495 days (range, 119-1109 days) in
the control group (Table 1).
In the control group, the mean number of days until
NAS was diagnosed was 2956 363 days (range,
22-1454 days). In the study group, the mean number of
days was 1896 202 days (range, 30-723 days; P5 0.38).
Graft survival, censored for death, shows equal results for
both groups (P5 0.68; Fig. 2). In the control group, the
median number of days until NAS was diagnosed was
1726 363 days (range, 71-346) compared to 1196 202
days (range, 48-216) in the study group.
Comparison of liver transplantations from DCD
donors only also showed equal graft survival; 7 (41%)
recipients in the study group developed NAS versus 12
(43%) recipients in the control group (P5 0.42).
In the control group, 10 (11%) recipients who
received a liver allograft from DBD donors developed
NAS versus 4 (9%) recipients in the study group. This
was not different (P5 0.89). Of all cases, 7 (21%)
recipients needed retransplantation for NAS.
TABLE 1. Donor, Transplant, and Recipient Characteristics
Urokinase Group (n 5 63) Controls (n 5 122) P Value
ET-DRI 1.8 6 0.3 1.8 6 0.3 0.56
Donor age, years 49.4 6 15.0 46.9 6 14.2 0.27
Donor BMI, kg/m2 25.2 6 3.3 24.0 6 3.3 0.03
FWIT, minutes 17.6 6 6.0 16.7 6 4.5 0.6
CIT, minutes 535.0 6 129.0 572.0 6 142.2 0.09
Recipient WIT, minutes 35.9 6 8.5 33.8 6 8.4 0.12
Recipient age, years 51.9 6 11.6 52.3 6 10.8 0.80
Recipient BMI, kg/m2 25.8 6 4.6 26.2 6 4.8 0.53
LabMELD 16.6 6 8.9 16.6 6 8.7 0.99
Time to NAS diagnosis, days 119 6 202 172 6 363
Time of follow-up, days 731 6 495 1731 6 1049
NOTE: Data are presented as mean6 SD. Time to NAS diagnosis and time of follow-up are presented as median6 SD.
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FIG. 2. Graft survival, censored for death.
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POSTREPERFUSION BLOOD LOSS
Table 2 shows the hematological and coagulation
parameters of both groups preoperative; the activated
partial thromboplastin time (aPTT) values during
anhepatic phase, after reperfusion, and after surgery;
the number of packed red blood cells (RBCs) trans-
fused during the first 24 hours from incision; and vol-
ume of autologous blood transfused.
Most remarkably, the mean preoperative aPTT in the
control group was 34.56 7.5 versus 38.56 7.5 seconds
in the study group (P 0.01), whereas aPTT did not
differ between the study group and control group in
the anhepatic phase after reperfusion and after
surgery.
The mean packed RBCs transfused in the control
group was 8.66 7.7 versus 5.66 6.2 units in the study
group (P< 0.01). The mean volume of autologous
blood transfused in the control group was 9196 1320
versus 9466 1166mL in the study group (P5 0.91).
Discussion
The present retrospective cohort study demonstrates
that flushing the donor liver with urokinase immedi-
ately before liver transplantation is safe but does not
prevent the development of NAS. It also did not lead
to an increase of transfusion requirements or disturbed
clotting.
In contrast to previous studies(15-17) describing a
decrease in the rate of NAS after thrombolysis before
liver transplantation, this study could not find a
decrease in NAS rate. The first study by Hashimoto
et al.(15) was a retrospective study, with the injection of
tPA in the donor hepatic artery on the back table in
DCD liver transplantations, resulting in significantly
less NAS development without increased blood loss.
Lang et al.(16) described a prospective study with dou-
ble perfusion of the donor liver with urokinase in
DCD liver transplantation, resulting in significantly
less NAS after 1 year of follow-up. Seal et al.(17)
described a retrospective analysis of DCD liver trans-
plantations with an intraoperative tPA injection, which
minimized the incidence of NAS without increasing
the need of intraoperative blood transfusion. When
looking closely at the dosage, type, and timing of the
thrombolytic agent, our study has some minor differ-
ences compared to the studies previously published. In
the study by Hashimoto et al.,(15) heparin was given to
the donor before withdrawal of life support, and the
liver allograft was perfused on the back table with
0.5mg/100 g graft tPA in the donor hepatic artery.
Lang et al.(16) perfused the arterial system of the donor
liver twice. First, they used a dosage of 2000mL HTK
solution that contained 2 MU urokinase for perfusion
through the arterial system. After trimming of the
donor liver, the arterial system was perfused again with
1 MU urokinase. In the study by Seal et al.,(17) heparin
was given to the donor before withdrawal of life sup-
port and, based on donor’s weight and before comple-
tion of the portal vein anastomosis, 100mg/kg tPA
was perfused in the donor liver to account for varia-
tions in graft size.(15-17) In our study, the donor liver
was perfused through the hepatic artery after inspec-
tion on the back table, with a high fixed dose of
250,000 IU of urokinase, manually pressurized, in
order to dissolve possible microthrombi.
To our knowledge, no previous studies have been
published that show superiority for tPA, compared to
urokinase, in low temperature circumstances.
Furthermore, the CIT in the study by Hashimoto
et al.(15) and Seal et al.(17) was much shorter. They
described a CIT of 4226 96 minutes and 5.16 1.2
hours, whereas the CIT in this study was 5726 142
minutes in the control group and 5356 129 minutes
in the study group. Lang et al.(16) described a CIT
between 2 and 13.5 hours but did not mention a mean
value.
The effect of thrombolytic agents has been reported
in the experimental as well as clinical transplantation of
various organs from DCD donors,(20-23) suggesting that
pretreatment with thrombolytic agents could be helpful
in human liver transplantation. A possible explanation
for not seeing a decrease in the rate of NAS in the cur-
rent study could be the timing of the intervention. The
therapeutic principle of administrating urokinase is to
TABLE 2. Hematological, Coagulation, and Transfusion





(n 5 122) P Value
Platelet count before surgery,
3109/L
128 6 96 118 6 90 0.47
PTT before surgery, seconds 20 6 8 17 6 5 <0.01
Fibrinogen before surgery, g/L 3.1 6 1.7 3.1 6 1.7 0.97
aPTT before surgery, seconds 39 6 8 35 6 8 <0.01
aPTT anhepatic phase, seconds 45 6 15 43 6 11 0.27
aPTT after reperfusion, seconds 70 6 23 72 6 28 0.57
aPTT after surgery, seconds 51 6 16 51 6 18 0.92
Packet cells, units 5.6 6 6.2 8.6 6 7.7 <0.01
Cell saver, mL 946 6 1166 919 6 1320 0.91
NOTE: Data are presented as mean6 SD.
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dissolve possible microthrombi from the peribiliary
microcirculation. It may be that administrating uroki-
nase immediately after organ procurement may be bene-
ficial, whereas late administration of urokinase may not
be able to prevent or dissolve microthrombosis. How-
ever, this hypothesis is not supported by Seal et al.,(17)
who administered tPA before completion of the portal
vein anastomosis in order to limit the effects of hypo-
thermia and dilution. The administration of urokinase
in the donor liver is not part of the liver transplantation
protocol in many other centers in the Eurotransplant
region. For that reason, we were not able to administer
urokinase during the donation procedure.
The absence of microthrombi in the microvascular
system of the biliary tree also has to be considered as a
possible explanation why urokinase in our hands did
not prevent NAS. In a study by op den Dries et al.,(24)
biopsies were taken from the donor bile duct in 128
liver transplant procedures. In the peribiliary plexus,
thrombi were found in only 2.7% of these bile ducts
from the livers that developed NAS, suggesting that
thrombosis may not play a critical role in the develop-
ment of NAS.
In a study by Hansen et al.,(25) histological evalua-
tions of 93 donor common bile ducts, received after
recirculation of the hepatic artery and before biliary
end-to-end anastomosis in LT, were performed. With
regard to NAS, they found that necrosis of the bile
duct wall, arteriolonecrosis, vascular lesions, and intra-
mural bleeding were statistically relevant associated
factors. Thrombosis was not of statistical influence on
occurrence of NAS. This also supports the theory that
thrombosis does not play a critical role in the develop-
ment of NAS.
Furthermore, Burlage et al.(26) believed that other
factors, such as increased experience, explain the
observed differences found in the study by Seal et al.(17)
The use of allogeneic and autologous blood as a
measurement of blood loss has been described before
by Hendriks et al.(27) Surprisingly, in this study, there
was significantly more need for packed RBC transfu-
sion in the control group, even though this group had
significantly better coagulation parameters preopera-
tively. A possible explanation for this may be a positive
effect of increasing experience within the transplanta-
tion team, as has been described previously.(27,28)
During the study period, the transfusion protocol has
not changed.
The extent and severity of NAS after liver trans-
plantation determines its prognosis and management.
Diffuse strictures have worse prognosis than local
strictures because of a lack of therapeutic options.
Even though we did not see a significant difference in
the rate of NAS, the number of retransplantations due
to NAS in the first year after transplantation could
potentially show a difference because of different sever-
ity of NAS. Of all cases of NAS in the control group,
6 (27%) recipients required retransplantation in the
first year after liver transplantation. Five (23%) recipi-
ents received a retransplantation in the first year after
liver transplantation and 1 (5%) recipient was placed
on the waiting list for retransplantation. In the study
group, none of the recipients received a retransplanta-
tion in the first year after liver transplantation, and 1
(9%) recipient was placed on the waiting list for
retransplantation. This difference was not significant
(P5 0.32). All other cases of NAS were treated con-
servatively by using balloon dilatation of the bile duct
combined with the placement of an intraductal stent.
The median number of interventions for NAS was
5.06 2.4 (range, 2.0-7.0) in the control group versus
4.56 4.2 (range, 2.0-8.0) in the study group.
Even though the median number of days of follow-
up is shorter in the study group, compared to the control
group, we do not believe this difference had an influence
on the outcome because the median number of days
until NAS diagnosis in both groups (1726 363 days
[range, 71-346 days] in the control group versus
1196 202 days [range, 48-216 days] in the study group)
is much shorter compared to the median number of
days of follow-up in both groups (17316 1049 days in
the study group versus 7316 495 days in the control
group). Because NAS is more common after DCD liver
transplantation, compared to DBD liver transplantation,
both groups were analyzed separately. When analyzed
separately, no difference was found in the incidence of
NAS after DCD liver transplantation (P5 0.42). Also,
no difference was found in the incidence of NAS after
DBD liver transplantation (P5 0.89).
This study has its limitations by its retrospective
character. A multi-institutional prospective study could
clarify this issue.
To conclude, arterial flushing of the donor liver
with urokinase immediately before implantation did
not lead to a lower incidence of NAS in this study, nor
did it lead to increased blood loss.
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